ABC | Volume 115, Nº2, Agosto 2020

Posicionamento Posicionamento sobre Uso de Antiplaquetários e Anticoagulantes nos Pacientes Infectados pelo Novo Coronavírus (COVID-19) – 2020 Arq Bras Cardiol. 2020; 115(2):292-301 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 14. Shi S, QinM, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25:e200950. [Epub ahead of print]. 15. Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res. 2020; 126(10):1443-55. 16. RuanQ, Yang K, WangW, Jiang L, Song J. Clinical predictors of mortality due to COVID- 19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 03; 46:845-8. 17. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. [Epub ahead of print]. 18. Peiris JSM, Chu CM , Cheng VCC, Chan KS , Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. 19. Inciardi RM, Lupi L, Zaccone G, Italia L, RaffoM , Tomasoni D, et al. Cardiac involvement in a patient with coronavírus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. [Epub ahead of print]. 20. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. L ancet Infect Dis. 2010; 10(2):83-92. 21. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, el al. ST- segment elevation in patients with Covid-19- a case series. N Engl J Med. 2020 Apr 17. [Epub ahead of print]. 22. Solomon MD, McNulty EJ , Rana JS , Leong TK, Lee C , Sung S, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020 May 19. [Epub ahead of print]. 23. Baldi E , Sechi GM, Mare C , Canevari F, Brancaglione A, Primi R, et al. Out- of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N Engl J Med. 2020 Apr 29. [Epub ahead of print]. 24. G , Henry BM, Sanchis-Gomar F. Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19). Eur J Prev Cardiol. 2020; 27(9):906-8. 25. Kochi AN , Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with Covid-19. J Cardiovasc Electrophysiol. 2020; 31(5):1003-8. 26. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6):1421-4. 27. Dolhnikoff M, Duarte-Neto AN, Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Saldiva PHN, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020; 18(6):1517-9. 28. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, CollangeO , et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-Dimer levels. Radiology. 2020 Apr 23; 201561. [Epub ahead of print]. 29. Nascimento JHP, Gomes BFO, Resende P, Petriz JLF, Rizk SI, Costa IBSS, et al. COVID-19 and hypercoagulable state: a new therapeutic perspective. Arq Bras Cardiol. 2020; 114(5):823-7. 30. Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. C lin Pharmacol Ther. 2019; 105(1):219-28. 31. Testa S , Prandoni P , Paoletti O , Morandini R, Tala M , Dellanoce C, et al. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the cremona experience. J Thromb Haemost. 2020; 18(6):1320-3. 32. Marsousi N, Daali Y, Fontana P, Reny J, Ancrenaz-Sirot V , Calmy A, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel activemetabolites. Clin Pharmacokinet. 2018; 57(10):1347-54. 33. Wang Y, Zhang D, Du G, Du R, Zhao J , Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-78. 34. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-3. 35. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments forcoronavirusdisease2019 (COVID-19):areview. JAMA.2020; 323(18)1824-36. 36. Geleris J, Sun Y, Platt J, Zucker J, BaldwinM , Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 May 7. [Epub ahead of print]. 37. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020 May 11:e208630. [Epub ahead of print]. 38. Tang W, Cao Z, Han M, Wang Z, Chen J, SunW , et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020May 14. [Epub ahead of print]. 39. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-9. 40. Vivas D, Rold´an V, Esteve-Pastor MA, Rold´an I, Tello-Montoliu A, Ruiz- Nodar JM, et al. Recomendaciones sobre el tratamento antitrombotico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espanola de Cardiologıa. Rev Esp Cardiol. 2020 Apr 22. [Epub ahead of print]. 41. Pereira MP, Lima EG, Serrano Júnior CV. Viral infections and atherothrombosis: another caution in the wake of COVID-19? Rev Assoc Med Bras. 2020; 66(3):366-9. 42. BassamAtallah B , Mallah SI , AlMahmeedW . Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 30. [Epub ahead of print]. 43. Thachil J,TangN,GandoS,FalangaA,CattaneoM,LeviM,etal. ISTH interim guidance on recognition andmanagement of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5):1023-26. 44. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CVDisease during the COVID-19 Pandemic; 2020. [citado 28May2020].Disponívelem :https://www.escardio.org/Education/COVID- 19-and-Cardiology/ESCCOVID-19-Guidance. 45. Mahmud E, Dauerman HL, Welt FG, Messenger JC, Rao SV, Grines C, et al. Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). C atheter Cardiovasc Interv. 2020 Apr 20. [Epub ahead of print]. 46. Abdelaziz HK, Patel B, Chalil S, Choudhury T. COVID-19 pandemic and acute myocardial infarction: management protocol from a British Cardiac Centre. Crit Pathw Cardiol. 2020; 19(2):55-7. 47. TanW, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol. 2020 Jun 15; 309:70-7. 48. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID‑19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020 Mar 11;1-3. [Epub ahead of print]. 301